Datapoint: Lilly Scores First-Ever Alopecia Areata Nod

With this week’s FDA approval, Eli Lilly and Incyte’s Olumiant is first-ever treatment for alopecia areata, an autoimmune disease that causes a severe form of hair loss. The JAK inhibitor was first approved in 2018 as a rheumatoid arthritis therapy. For the treatment of rheumatoid arthritis, Olumiant holds covered or better status for 61% of all insured lives. Just 11% of insured lives have preferred access to Olumiant.

SOURCE: MMIT Analytics, as of 6/15/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 25

Datapoint: N.C. Blues Says Specialty Pharmacy Management Reduced Premiums

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Idaho Completes Medicaid Redeterminations

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 20

Datapoint: Elevance’s New York Subsidiary, Catholic Health Team Up on Value-Based Care

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today